Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

49.37USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$49.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
233,751
52-wk High
$57.33
52-wk Low
$9.40

Latest Key Developments (Source: Significant Developments)

Esperion prices public offering of common stock at $49 per share
Wednesday, 9 Aug 2017 09:20pm EDT 

Aug 9 (Reuters) - Esperion Therapeutics Inc :Esperion prices public offering of common stock.Announces public offering of 3.1 million shares of its common stock, offered at a price to public of $49.00 per share.  Full Article

Esperion announces proposed public offering of common stock
Tuesday, 8 Aug 2017 04:31pm EDT 

Aug 8 (Reuters) - Esperion Therapeutics Inc ::Esperion announces proposed public offering of common stock.Says ‍intends to offer and sell $150 million of its common stock in an underwritten public offering​.Esperion Therapeutics - to use net proceeds from offering, other existing capital resources, to fund clear outcomes cardiovascular outcomes trial​.  Full Article

Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Esperion Therapeutics Inc :Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​.Says ‍1002-038 study meets primary endpoint with a robust 64% LDL-C lowering efficacy​.Says ‍combination therapy was observed to be safe and well-tolerated​.Says ‍there were no reported serious adverse events (SAES), no difference in muscle-related adverse events​.  Full Article

Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor
Wednesday, 26 Jul 2017 04:30pm EDT 

July 26 (Reuters) - Esperion Therapeutics Inc ::Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor.Esperion therapeutics inc- ‍top-line results are expected by q1 of 2018 from study​.Esperion therapeutics inc- ‍we don't intend to explore bempedoic acid added-on to a pcsk9i in further studies due to their limited use to date​.Esperion therapeutics- ‍in phase 2 study, anticipate will see favorable safety, tolerability and incremental ldl-c lowering efficacy from bempedoic acid​.  Full Article

Esperion says FDA confirms regulatory pathway to approval its combination cholestrol treatment
Monday, 26 Jun 2017 04:05pm EDT 

June 26 (Reuters) - Esperion Therapeutics Inc -:Esperion announces FDA confirmation of regulatory pathway to approval for the combination of bempedoic acid and ezetimibe.Says phase 3 bempedoic acid / ezetimibe combination bridging study to initiate by Q4 of 2017.Esperion Therapeutics - on track to submit both bempedoic acid / ezetimibe combination and bempedoic acid global regulatory filings for an ldl-c lowering indication by h1 2019.Esperion Therapeutics says top-line results for for the bempedoic acid / ezetimibe combination pill trial expected by end of 2018.  Full Article

Esperion reports Q1 net loss per common share $1.80
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Esperion Therapeutics Inc :Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results.Esperion Therapeutics Inc - esperion expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million.Qtrly net loss per common share $1.80.  Full Article

Boxer Capital reports 5.3 pct passive stake in Esperion Therapeutics
Thursday, 23 Mar 2017 04:32pm EDT 

Esperion Therapeutics Inc : Boxer Capital LLC reports 5.3 percent passive stake in Esperion Therapeutics Inc as of March 20 - SEC filing Source: (http://bit.ly/2mZu8Mb) Further company coverage: [ESPR.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid
Monday, 20 Mar 2017 07:30am EDT 

Esperion Therapeutics Inc : Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid . Esperion therapeutics inc - on track to submit nda for an ldl-c lowering indication by 1h 2019 . Esperion therapeutics- remain focused on completing global pivotal phase 3 program for bempedoic acid . Esperion therapeutics inc - remain focused on reporting top-line results from our long-term safety and tolerability study by q2 2018 .Esperion therapeutics- expects to submit nda for cardiovascular disease risk reduction indication to fda, marketing authorization application to ema by 2022.  Full Article

Esperion posts Q4 loss per share $1.29
Wednesday, 22 Feb 2017 07:30am EST 

Esperion Therapeutics Inc : Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results . Esperion Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million . Esperion Therapeutics Inc says estimates that current cash resources are sufficient to fund operations into early 2019 . Qtrly loss per share $1.29 .Esperion Therapeutics Inc - company estimates that current cash resources are sufficient to fund operations into early 2019.  Full Article

Esperion Therapeutics reports qtrly loss per share $0.77
Thursday, 3 Nov 2016 04:05pm EDT 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million . Esperion Therapeutics Inc - qtrly loss per share $0.77 . Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S .Esperion Therapeutics provides bempedoic acid development program updates; reports third quarter 2016 financial results.  Full Article

BRIEF-Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc

* Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​ Source text (http://bit.ly/2x6jGbc) Further company coverage: